Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Genetics & Genomics
Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development
July 16th, 2008
Antigen Discovery Inc. ("ADI", formerly ImmPORT Therapeutics Inc.), a leader in high throughput antigen/biomarker discovery using advanced genomics and proteomics tools, announced that the Company was awarded a Phase II SBIR from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Center for Research Resources (NCRR). The $3 million grant will fund efforts to further develop ADI's protein microarray based serodiagnostic platform for applications in biodefense and emerging infectious diseases. ADI will collaborate with investigators at the Proteomics Core facility of the Pacific Southwest Regional Center of Excellence (PSW RCE), located at the University of...
Source: Vaccine Weekly (2008-07-16)
|
